About Mas-related G-protein coupled receptor member X1
Mas-related G-protein coupled receptor member X1 (MRGPRX1) is a protein
from Homo sapiens identified by UniProt accession
Q96LB2, 322 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Mas-related G-protein coupled receptor member X1 |
| UniProt accession | Q96LB2 |
| Gene | MRGPRX1 |
| Organism | Homo sapiens |
| Length | 322 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- Recurrent infection due to specific granule deficiency · score 0.04
- neutrophil immunodeficiency syndrome · score 0.04
- hepatorenocardiac degenerative fibrosis · score 0.04
- renal cysts and diabetes syndrome · score 0.04
- Mayer-Rokitansky-Kuster-Hauser syndrome · score 0.03
- renal hypodysplasia/aplasia 3 · score 0.03
- kidney disease · score 0.03
- immunodeficiency 81 · score 0.03
- 46,XX ovotesticular disorder of sex development · score 0.03
- hyperparathyroidism 2 with jaw tumors · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96LB2-F1 | alphafold | PREDICTED | 82.80 | — |
Amino-acid sequence (322 residues)
MDPTISTLDT ELTPINGTEE TLCYKQTLSL TVLTCIVSLV GLTGNAVVLW LLGCRMRRNA FSIYILNLAA ADFLFLSGRL IYSLLSFISI PHTISKILYP VMMFSYFAGL SFLSAVSTER CLSVLWPIWY RCHRPTHLSA VVCVLLWALS LLRSILEWML CGFLFSGADS AWCQTSDFIT VAWLIFLCVV LCGSSLVLLI RILCGSRKIP LTRLYVTILL TVLVFLLCGL PFGIQFFLFL WIHVDREVLF CHVHLVSIFL SALNSSANPI IYFFVGSFRQ RQNRQNLKLV LQRALQDASE VDEGGGQLPE EILELSGSRL EQ
Explore Mas-related G-protein coupled receptor member X1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets